论文部分内容阅读
作者在53例急性粒细胞白血病(AML)和3例急性淋巴细胞白血病(ALL)用CD1a(Langerhans 细胞/LC 的特殊标记)和粒系标记(CD11,CD13,CD14,CD15,CD33,HLA-DR)进行免疫荧光和免疫电镜研究。结果:作为阴性对照的ALL 中CD1a 抗原均为阴性.FAB 分类的M1,M2和M3亦无CD1a 抗原。5例M4中2例阳性,37例M5中9例阳性。11例CD1a 阳性和42例CD1a 阴性者在细胞遗传学和对治疗的反应上均无区别。CD1a 和粒系标记之间亦无关系.与HLA-DR 亦无显著关系。CD1a 阳性和阴性病例的临床表现(特别是皮肤表现)无相关性。作者认为在白血病细胞中CD1a 表现可有三种
The authors used CD1a (Langerhans cell / LC specific marker) and myeloid markers (CD11, CD13, CD14, CD15, CD33, HLA-DR ) For immunofluorescence and immunoelectron microscopy. Results: CD1a antigen was negative in ALL as a negative control, and there was no CD1a antigen in M1, M2 and M3 of FAB classification. 2 cases were positive in 5 cases of M4 and 9 cases were positive in 37 cases of M5. Eleven patients with CD1a-positive and 42 patients with CD1a-negative had no difference in cytogenetics and response to treatment. There was also no relationship between CD1a and myeloid markers, nor did it correlate with HLA-DR. No correlation was found between the clinical manifestations of CD1a positive and negative cases (especially skin manifestations). The authors suggest that there are three manifestations of CD1a in leukemic cells